aibioAtossa Therapeutics regains Nasdaq minimum bid price compliance
Tickers ATOS
Atossa Therapeutics received a Nasdaq letter on February 17, 2026 saying it regained the $1.00 minimum closing bid price. The stock met the test on February 13, 2026, the last trading day before the extended deadline, after a February 2025 notice and an extension granted in August 2025.
Key facts
- Company
- Atossa Therapeutics, Inc. (NASDAQ: ATOS)
- News type
- Listings
- Primary source
- ATOSSA THERAPEUTICS, INC. Form 8-K filed February 17, 2026 (SEC EDGAR)
Atossa Therapeutics, Inc. (Nasdaq: ATOS) received a letter from The Nasdaq Stock Market LLC on February 17, 2026, saying the company had regained compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market. The company reported the letter in a Form 8-K filed February 17, 2026 under Item 3.01, which covers notices of a failure to meet a continued listing rule. The shares will remain listed and traded on the Nasdaq Capital Market.
What the rule required
Nasdaq Listing Rule 5550(a)(2) requires a minimum closing bid price of $1.00 a share for companies on the Capital Market. To regain compliance, Atossa had to keep the closing price at or above $1.00 for at least 10 consecutive trading days. The 8-K says that requirement was met as of the close of trading on February 13, 2026.
How the deficiency unfolded
On February 21, 2025, Nasdaq notified Atossa that its common stock had failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. The company was first given until August 20, 2025 to regain compliance. The gap between the first notice and the compliance letter ran from February 21, 2025 to February 17, 2026.
Atossa then asked for more time. On August 21, 2025, Nasdaq told the company that its deadline had been extended by 180 days, to February 17, 2026. The compliance letter arrived on the last day of that extended period, and the 8-K describes the company's compliance as having been met before the letter was sent.
What the result does and does not show
The letter restores the company to the standard listing rule, but it says nothing about the reason the stock traded below $1.00 for so long, or about whether the price will hold above that level. The 8-K does not give a price or a reason for the rise. A stock that has met the test can fall below $1.00 again.
The compliance also does not address the company's business. Atossa's 2024 annual report on Form 10-K describes it as a clinical-stage biopharmaceutical company developing treatments in oncology, with a focus on women's breast cancer. Its lead drug candidate is oral (Z)-endoxifen, which the company is developing for the prevention and treatment of breast cancer. The report describes (Z)-endoxifen as an active metabolite of tamoxifen, an FDA-approved drug, and says the company's planned trials of the drug may not enroll enough subjects in time or be completed at all.
The report says the drug may overcome some shortcomings of tamoxifen, but it also says that up to 50% of breast cancer survivors who take tamoxifen do not reach therapeutic (Z)-endoxifen levels, which is the gap the company's product is meant to close. That is the company's claim, and the report describes the trials as still to be run.
The report also lists the loss of its chief executive officer as a risk that could adversely affect the business. The Nasdaq letter confirms only that the stock price met a listing test in February 2026. It does not show that the drug has passed a trial, and the company remains a clinical-stage developer.
Who signed
Mark J. Daniel, Chief Financial Officer and Principal Financial and Accounting Officer, signed the 8-K for Atossa Therapeutics, Inc. on February 17, 2026.